Annual Report

Overview

The report describes TransThera's 2025 listing on the Main Board of the Hong Kong Stock Exchange and continued development of its innovative pharmaceutical pipeline. Tinengotinib advanced to NDA acceptance in China, while clinical programs expanded across oncology and other indications. The company also entered a Neurocrine Biosciences collaboration with potential value of US$881.5 million.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: Ends 31 December 2025
Publication date: 31 March 2026
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services